Dosing and administration of MENVEO 2-vial presentation1

Vaccination may not protect all recipients.
Not actual patients.

FDA-approved dosing for MENVEO1

For infants:

MENVEO 2-vial presentation is approved for use in the US for infants as young as 2 months of age.

2 months of age dosing image

4-DOSE SERIES with a single dose (0.5 mL) at 2, 4, 6, and 12 months of age.1

7 through 23 months of age dosing image

2-DOSE SERIES (0.5 mL each) with the second dose administered in the second year of life, at least 3 months after the first dose.1

2 through 10 years of age dosing image

A SINGLE DOSE (0.5 mL). For children aged 2 through 5 years at continued high risk of meningococcal disease, a second dose (0.5 mL) may be administered 2 months after the first dose.1

11 through 55 years of age dosing image

A SINGLE DOSE (0.5 mL).1
A SINGLE BOOSTER DOSE (0.5 mL) may be administered to individuals who are at continued risk for meningococcal disease if at least 4 years have elapsed since a prior dose of a MenACWY vaccine.1

The safety and effectiveness of MENVEO 1-vial presentation in children aged younger than 10 years have not been established.1

MENVEO 1-vial* is approved for use as a single dose in adolescents and adults aged 10 through 55 years. A single booster dose may be administered to individuals aged 15 through 55 years who are at continued risk of meningococcal disease, if at least 4 years have elapsed since a prior dose of a MenACWY vaccine.

 

* MENVEO 2-vial is also approved for use in individuals aged 10 through 55 years.

Reconstitution for MENVEO 2-vial presentation1

MENVEO 2-vial presentation is a solution for intramuscular injection supplied in 2 vials, the contents of which must be combined prior to administration.

  • MenCYW-135 liquid conjugate component (gray cap)
  • MenA lyophilized conjugate component (orange cap)

After reconstitution, a single dose of MENVEO is 0.5 mL. Please note that neither component should be given alone.

MENVEO 2-vial presentation can be reconstituted in 3 steps1: PULL, MIX, and SHAKE

Syringe pulling contents from tilted Vial 1

PULL the entire contents of MenCYW-135 liquid conjugate (Vial 1) from the vial while slightly tilting.

Syringe putting contents into Vial 2

MIX the MenCYW-135 liquid with the MenA lyophilized conjugate (Vial 2).

Syringe inserted into Vial 2, both upside-down

Invert the vial and SHAKE well until the lyophilized conjugate component is completely dissolved.

After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine and administer intramuscularly.

  • FDA=Food and Drug Administration; MenA=meningococcal serogroup A; MenACWY=meningococcal serogroups A, C, W, Y; MenCYW-135=meningococcal serogroups C, Y, W-135.

Indication & Important Safety Info

Indication

Important Safety Information for MENVEO

Indication

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

Important Safety Information for MENVEO

  • Do not administer MENVEO to individuals with a severe allergic reaction (eg, anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
  • Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO
  • Syncope (fainting) has occurred in association with administration of MENVEO. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MENVEO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W, even if they develop antibodies following vaccination with MENVEO
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer MENVEO to individuals with a history of GBS should take into account the expected benefits and potential risks
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer MENVEO to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
  • Common solicited adverse reactions with MENVEO among children initiating vaccination: at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age who received MENVEO were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Across all age groups, some events were severe. Similar rates of solicited adverse reactions among adolescents and adults were observed following a single booster dose
  • In two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation
  • Vaccination with MENVEO may not result in protection in all vaccine recipients

 

Please see full Prescribing Information for MENVEO.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Prescribing Information for MENVEO.